All In Biotech

Drug Trial Radar · NCT00314249

Study of Milnacipran for the Treatment of Fibromyalgia

A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.

Last checked: Nov 20, 2026Latest source record: Jan 20, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 1,025 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,025

Actual

Start

Apr 2006

Primary completion

Jun 2008

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
Collaborators
Cypress Bioscience, Inc.
First posted
Apr 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

  • PlaceboDrug

    Placebo, oral administration, twice daily for 12 weeks

  • Milnacipran 100mgDrug

    Milnacipran 100mg per day (50mg BID \[twice a day\])

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Syndrome Responder StatusTime frame: At the end of the three-month stable dose treatment phase
  2. Composite Pain Responder StatusTime frame: At the end of three-month stable dose treatment phase

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Forest Investigative Site

    Tuscaloosa, Alabama

  • Forest Investigative Site

    Fresno, California

  • Forest Investigative Site

    Pismo Beach, California

  • Forest Investigative Site

    Vista, California

  • Forest Investigative Site

    St. Petersburg, Florida

  • Forest Investigative Site

    St. Petersburg, Florida

  • Forest Investigative Site

    Stuart, Florida

  • Forest Investigative Site

    Atlanta, Georgia

  • Forest Investigative Site

    Springfield, Massachusetts

  • Forest Investigative Site

    Worcester, Massachusetts

  • Forest Investigative Site

    Omaha, Nebraska

  • Forest Investigative Site

    Haddon Heights, New Jersey

  • Forest Investigative Site

    Johnson City, New York

  • Forest Investigative Site

    Syracuse, New York

  • Forest Investigative Site

    Greensboro, North Carolina

  • Forest Investigative Site

    Cleveland, Ohio

  • Forest Investigative Site

    Columbus, Ohio

  • Forest Investigative Site

    Toledo, Ohio

  • Forest Investigative Site

    Eugene, Oregon

  • Forest Investigative Site

    Mechanicsburg, Pennsylvania

  • Forest Investigative Site

    Anderson, South Carolina

  • Forest Investigative Site

    Greer, South Carolina

  • Forest Investigative Site

    Richardson, Texas

  • Forest Investigative Site

    Virginia Beach, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.